Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Bidur Banjara, Nabin Poudel, Kimberly B Garza, Salisa Westrick, Heather P Whitley, David Redden & Surachat Ngorsuraches. (2022) Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Patient Preference and Adherence 16, pages 3415-3428.
Read now
Read now
Yuyu Lv, Ru Ren, Chengxiang Tang, Kuimeng Song, Shunping Li & Haipeng Wang. (2022) Preferences for Patients with Type 2 Diabetes Mellitus for Medications in Shandong Province, China: A Discrete Choice Experiment. Patient Preference and Adherence 16, pages 2335-2344.
Read now
Read now
Tracy J Sims, Kristina S Boye, Susan Robinson & Tessa Kennedy-Martin. (2022) Treatment-Related Attributes of Diabetes Therapies and How People with Type 2 Diabetes Report Their Impact on Indicators of Medication-Taking Behaviors. Patient Preference and Adherence 16, pages 1919-1939.
Read now
Read now
Yitian Lang, Bin Wu, Zhilin Sun, Erjia Ye, Guanshen Dou & Xin Guan. (2022) Patient Preference for Biologic Treatments of Psoriasis in the Chinese Setting. Patient Preference and Adherence 16, pages 1071-1084.
Read now
Read now
Vivian T Thieu, Susan Robinson, Tessa Kennedy-Martin, Kristina S Boye & Luis-Emilio Garcia-Perez. (2019) Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes. Patient Preference and Adherence 13, pages 561-576.
Read now
Read now
Ellen M Janssen, Daniel R Longo, Joan K Bardsley & John FP Bridges. (2017) Education and patient preferences for treating type 2 diabetes: a stratified discrete-choice experiment. Patient Preference and Adherence 11, pages 1729-1736.
Read now
Read now
A. Brett Hauber, Engels N. Obi, Mark A. Price, Diane Whalley & Chun-Lan Chang. (2017) Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure. Current Medical Research and Opinion 33:11, pages 2027-2038.
Read now
Read now
Emuella M. Flood, Kelly F. Bell, Marie C. de la Cruz & France M. Ginchereau-Sowell. (2017) Patient preferences for diabetes treatment attributes and drug classes. Current Medical Research and Opinion 33:2, pages 261-268.
Read now
Read now
Katie D Stewart, Joseph A Johnston, Louis S Matza, Sarah E Curtis, Henry A Havel, Stephanie A Sweetana & Heather L Gelhorn. (2016) Preference for pharmaceutical formulation and treatment process attributes. Patient Preference and Adherence 10, pages 1385-1399.
Read now
Read now
A. Brett Hauber, Hiep Nguyen, Joshua Posner, Iftekhar Kalsekar & James Ruggles. (2016) A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Current Medical Research and Opinion 32:2, pages 251-262.
Read now
Read now
Carlos Morillas, Rosa Feliciano, Pablo Fernández Catalina, Carla Ponte, Marta Botella, João Rodrigues, Enric Esmatjes, Javier Lafita, Luis Lizán, Ignacio Llorente, Cristóbal Morales, Jorge Navarro-Pérez, Domingo Orozco-Beltran, Silvia Paz, Antonio Ramirez de Arellano, Cristina Cardoso & Maribel Tribaldos Causadias. (2015) Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Preference and Adherence 9, pages 1443-1458.
Read now
Read now
Davida F Kruger, Susan LaRue & Phil Estepa. (2015) Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes, Metabolic Syndrome and Obesity 8, pages 49-56.
Read now
Read now
Heather N Woodward & Sarah L Anderson. (2014) Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Preference and Adherence 8, pages 789-803.
Read now
Read now
Rajesh K Rajpal, Bryan Ross, Sachin D Rajpal & Khoa Hoang. (2014) Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence. Patient Preference and Adherence 8, pages 925-931.
Read now
Read now
Articles from other publishers (25)
Caroline D Crossey, Andrew Garcia & Lucas A Berenbrok. (2022) An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation. American Journal of Health-System Pharmacy 79:22, pages 1978-1979.
Crossref
Crossref
Donna-Marie Wynter-Adams, Peta-Gaye Thomas-Brown, Marcia Williams, Lisa Bromfield & Janice Bunting-Clarke. (2022) Assessment of rational use of medicines for chronic non-communicable diseases: A cross-sectional design in a public access clinic in Jamaica. Journal of Public Health Research 11:3, pages 227990362211263.
Crossref
Crossref
Yuankai Huang, Qixiang Huang, Ailin Xu, Mengqing Lu & Xiaoyu Xi. (2022) Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment. Frontiers in Public Health 9.
Crossref
Crossref
Sreenivasa Murthy, Pankaj Aneja, Arthur Joseph Asirvatham, Lise Lotte N. Husemoen, Nicolai A. Rhee & Jothydev Kesavadev. (2021) Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market. PharmacoEconomics - Open 5:2, pages 261-273.
Crossref
Crossref
Axel C. Mühlbacher, Andrew Sadler & Christin Juhnke. (2021) Personalized diabetes management: what do patients with diabetes mellitus prefer? A discrete choice experiment. The European Journal of Health Economics 22:3, pages 425-443.
Crossref
Crossref
Muhammad Umair Khan, Jo-anne Brien & Parisa Aslani. (2020) The use of discrete choice experiments in adherence research: A new solution to an old problem. Research in Social and Administrative Pharmacy 16:10, pages 1487-1492.
Crossref
Crossref
Marta Kurczewska-Michalak, Przemysław Kardas & Mikołaj Czajkowski. (2020) Patients’ Preferences and Willingness to Pay for Solid Forms of Oral Medications—Results of the Discrete Choice Experiment in Polish Outpatients. Pharmaceutics 12:3, pages 236.
Crossref
Crossref
Matthew Reaney, Elizabeth Bush, Mary New, Jean Paty, Aude Roborel de Climens, Soren E. Skovlund, Linda Nelsen, Emuella Flood & Adam Gater. (2019) The Potential Role of Individual-Level Benefit-Risk Assessment in Treatment Decision Making: A DIA Study Endpoints Community Workstream. Therapeutic Innovation & Regulatory Science 53:5, pages 630-638.
Crossref
Crossref
Christin Juhnke & Axel C. Mühlbacher. (2019) Patientenpräferenzen: Wünsche von Betroffenen mit Diabetes mellitusPatient preferences: what do diabetes patients want?. Der Diabetologe 15:6, pages 534-541.
Crossref
Crossref
Hitoshi Ishii, Hiroki Shin, Takahiro Tosaki, Tatsuya Haga, Yoshiki Nakajima, Toshihiko Shiraiwa, Nobuaki Watanabe, Miyuki Koizumi, Hiroki Nakajima, Sadanori Okada, Tsuyoshi Mashitani, Takako Mohri & Yasuhiro Akai. (2018) Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ). Diabetes Therapy 9:3, pages 1001-1019.
Crossref
Crossref
Carol Mansfield, Mirko V. Sikirica, Amy Pugh, Christine M. Poulos, Victoria Unmuessig, Raul Morano & Alan A. Martin. (2017) Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey. Diabetes Therapy 8:6, pages 1365-1378.
Crossref
Crossref
Jin Du, Li Liang, Hui Fang, Fengmei Xu, Wei Li, Liya Shen, Xueying Wang, Chun Xu, Fang Bian & Yiming Mu. (2017) Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study). Diabetes, Obesity and Metabolism 19:11, pages 1513-1520.
Crossref
Crossref
Axel Mühlbacher & Susanne Bethge. (2015) What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. The European Journal of Health Economics 17:9, pages 1125-1140.
Crossref
Crossref
Ellen M. Janssen, Jodi B. Segal & John F. P. Bridges. (2016) A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes. The Patient - Patient-Centered Outcomes Research 9:5, pages 465-479.
Crossref
Crossref
. 2016. Drug Delivery. Drug Delivery
481
522
.
Sieta T. de Vries, Folgerdiena M. de Vries, Thijs Dekker, Flora M. Haaijer-Ruskamp, Dick de Zeeuw, Adelita V. Ranchor & Petra Denig. (2015) The Role of Patients’ Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes. PLOS ONE 10:10, pages e0139755.
Crossref
Crossref
Tracey-Lea Laba, Beverley Essue, Merel Kimman & Stephen Jan. (2014) Understanding Patient Preferences in Medication Nonadherence: A Review of Stated Preference Data. The Patient - Patient-Centered Outcomes Research 8:5, pages 385-395.
Crossref
Crossref
Esther S. Kim & Emma D. Deeks. (2015) Empagliflozin/Linagliptin: A Review in Type 2 Diabetes. Drugs 75:13, pages 1547-1557.
Crossref
Crossref
Joseph F. LevyPatrick D. MeekMarjorie A. Rosenberg. (2014) US-Based Drug Cost Parameter Estimation for Economic Evaluations. Medical Decision Making 35:5, pages 622-632.
Crossref
Crossref
Ibrahim, A W, Pindar, S K, Yerima, M M, Rabbebe, I B, Shehu, S, Garkuwa, H A, Bashir, I Y, Wakil, M A, Yahya & S J. (2015) Medication-related factors of non adherence among patients with schizophrenia and bipolar disorder: Outcome of a cross-sectional survey in Maiduguri, North-eastern Nigeria. Journal of Neuroscience and Behavioral Health 7:5, pages 31-39.
Crossref
Crossref
Axel C. Mühlbacher & A. Kaczynski. (2015) Patientenpräferenzen in der medikamentösen Therapie von Diabetes Mellitus Typ 2Patients’ preferences in the medicamentous treatment of diabetes mellitus type 2. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 58:4-5, pages 452-466.
Crossref
Crossref
A. Brett Hauber, Kaan Tunceli, Jui-Chen Yang, Ira Gantz, Kimberly G. Brodovicz, Charles M. Alexander, Michael J. Davies & Larry Radican. (2015) A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus. Diabetes Therapy 6:1, pages 75-84.
Crossref
Crossref
Trudy Ann Cameron. (2014) Valuing Morbidity in Environmental Benefit-Cost Analysis. Annual Review of Resource Economics 6:1, pages 249-272.
Crossref
Crossref
Stephen S. Johnston, Hiep Nguyen, Eugene Felber, Katherine Cappell, James K. Nelson, Bong-Chul Chu & Iftekhar Kalsekar. (2014) Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States. Advances in Therapy 31:11, pages 1119-1133.
Crossref
Crossref
Giuseppe Derosa & Pamela Maffioli. (2014) Safety and efficacy of albiglutide—results from two trials. Nature Reviews Endocrinology 10:9, pages 514-516.
Crossref
Crossref